Clinical Trial Update: A Safety Study of NNZ-2566 in Patients With Fragile X Syndrome [Phase 2]

View source ↗

Summary

Phase 2 safety study of NNZ-2566 in Fragile X Syndrome completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fragile Syndrome

Drugs mentioned

• NNZ-2566

Snippet

Sponsor: Neuren Pharmaceuticals Limited | Conditions: Fragile X Syndrome | Phase 2 | Status: COMPLETED